Biocept Inc.
| NASDAQ: BIOC |
| Healthcare / Medical Diagnostics & Research / USA |
| 0.9000 | -0.0615 | -6.40% | Vol 275.52K | 1Y Perf -77.22% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 0.8677 | ASK | 0.9800 | ||
| Open | 0.9800 | Previous Close | 0.9615 | ||
| Pre-Market | - | After-Market | 0.94 | ||
| - - | 0.04 4.44% |
| Target Price | 8.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 844.44 | Finscreener Ranking | ★★★★★ 64.47 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.06 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 56.06 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.72 | Earnings Rating | Buy | |
| Market Cap | 15.23M | Earnings Date | 15th Aug 2022 | |
| Alpha | -0.05 | Standard Deviation | 0.35 | |
| Beta | 0.66 |
Today's Price Range 0.90001.00 | 52W Range 0.96154.53 | 5 Year PE Ratio Range -1.90-0.4000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -13.46% | ||
| 1 Month | -34.31% | ||
| 3 Months | -60.00% | ||
| 6 Months | -76.62% | ||
| 1 Year | -77.22% | ||
| 3 Years | -91.96% | ||
| 5 Years | -99.79% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -78.72 | |||
ROE last 12 Months | -25.68 | |||
ROA (5Y Avg) | -16.36 | |||
ROA last 12 Months | -14.60 | |||
ROC (5Y Avg) | -294.05 | |||
ROC last 12 Months | -18.04 | |||
Return on invested Capital Q | -5.44 | |||
Return on invested Capital Y | -7.68 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 2.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.90 | ||||
| 0.48 | ||||
| 0.28 | ||||
| 8.50 | ||||
| 18.40 | ||||
| 0.12 | ||||
| 0.48 | ||||
| 2.19 | ||||
| 2.32M | ||||
| Forward PE | -0.82 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.10 | ||||
| 3.40 | ||||
| 0.23 | ||||
| 0.33 | ||||
| -27.20 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 38.40 | ||||
| -12.30 | ||||
| -8.00 | ||||
| -345.90 | ||||
| -12.91 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 63.44M | ||||
| 3.75 | ||||
| 155.41 | ||||
| 73.75 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.24 | -0.16 | 33.33 |
| Q04 2021 | - | -0.27 | - |
| Q03 2021 | 0.09 | 0.03 | -66.67 |
| Q02 2021 | - | -0.14 | - |
| Q01 2021 | - | 0.19 | - |
| Q04 2020 | - | 0.14 | - |
| Q03 2020 | -0.48 | -0.43 | 10.42 |
| Q02 2020 | -0.40 | -0.50 | -25.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.09 | 91.00 | Positive |
| 9/2022 QR | -0.16 | 84.31 | Positive |
| 12/2022 FY | -0.66 | - | - |
| 12/2023 FY | -1.40 | - | - |
| Next Report Date | 15th Aug 2022 |
| Estimated EPS Next Report | -0.09 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 275.52K |
| Shares Outstanding | 16.92K |
| Shares Float | 16.92M |
| Trades Count | 842 |
| Dollar Volume | 261.39K |
| Avg. Volume | 124.66K |
| Avg. Weekly Volume | 180.80K |
| Avg. Monthly Volume | 94.69K |
| Avg. Quarterly Volume | 98.49K |
Biocept Inc. (NASDAQ: BIOC) stock closed at 0.9 per share at the end of the most recent trading day (a -6.4% change compared to the prior day closing price) with a volume of 275.52K shares and market capitalization of 15.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 95 people. Biocept Inc. CEO is Michael W. Nall.
The one-year performance of Biocept Inc. stock is -77.22%, while year-to-date (YTD) performance is -75.14%. BIOC stock has a five-year performance of -99.79%. Its 52-week range is between 0.9615 and 4.53, which gives BIOC stock a 52-week price range ratio of -1.72%
Biocept Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 0.48, a price-to-sale (PS) ratio of 0.28, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of -14.60%, a ROC of -18.04% and a ROE of -25.68%. The company’s profit margin is -12.91%, its EBITDA margin is -8.00%, and its revenue ttm is $63.44 Million , which makes it $3.75 revenue per share.
Of the last four earnings reports from Biocept Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Biocept Inc.’s next earnings report date is 15th Aug 2022.
The consensus rating of Wall Street analysts for Biocept Inc. is Strong Buy (1), with a target price of $8.5, which is +844.44% compared to the current price. The earnings rating for Biocept Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biocept Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biocept Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.88, ATR14 : 0.11, CCI20 : -144.95, Chaikin Money Flow : -0.51, MACD : -0.16, Money Flow Index : 13.11, ROC : -42.68, RSI : 21.72, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 21.50, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biocept Inc. in the last 12-months were:
Biocept Inc.
Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cells and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.
CEO: Michael W. Nall
Telephone: +1 858 320-8200
Address: 5810 Nancy Ridge Drive, San Diego 92121, CA, US
Number of employees: 95
TipRanks News for BIOC
Wed, 27 Apr 2022 18:55 GMT Biocept (BIOC) Receives a Buy from Brookline Capital Markets
- TipRanks. All rights reserved.
